

Listing of Claims:


Please note the claims remain as follows, noting also that this listing of claims technically replaces all prior versions, and prior listings of claims in the application:

1. (Previously Presented): A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

-G₁ is a radical (II)




wherein -R' is an electron pair or a (C₁-C₃)-alkyl radical; with the condition that


- (i) when -R' is an electron pair, a is a N=C double bond and the fused ring



is the biradical




thus radical (II) is (IIa'), and




(IIa')

(ii) when -R' is a (C₁-C₃)-alkyl radical, a is a N-C single bond and the fused ring

is the triradical



thus radical (II) is (IIa'');




(IIa'')

wherein -R₁ to -R₁₂ represent radicals, same or different, selected from the group consisting of H, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein -B- is a biradical selected from the group consisting of -CONH-, -NR₁₃-, -O-, -(CH₂)_nNH-, -(CH₂)_nO-, and -CO[NHCHR^{''}CO]_mO-; wherein -R₁₃ is selected from the group consisting of H, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy and (C₁-C₄)-alkylamino; -R^{''} are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3 and m is an integer from 1 to 3;


-L- is a single covalent bond or a covalent linking biradical selected from the following ones;



wherein -R^{'''} and -R^{'''} are radicals, same or different, selected from the group consisting of H and (C₁-C₃)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

-G₂ is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

2. (Previously Presented): The compound according to claim 1, wherein (II) is the radical (IIa').




3. (Original): The compound according to claim 2, wherein -B- is selected from the group consisting of -CONH- and -NR₁₃- .

4. (Original): The compound according to claim 2, wherein -B- is -CO[NHCHR"CO]_mO- .

5. (Original): The compound according to claim 4, wherein m = 2, the leftward -R" is a glycinic side chain, and the rightward -R" is an arginine side chain.

6. (Previously Presented): The compound according to claim 2, wherein -L- is a single covalent bond.

7. (Previously Presented): The compound according to claim 2, wherein -L- is a covalent linking biradical selected from the following ones.




8. (Previously Presented): The compound according to claim 7, wherein -L- is the biradical

$-(\text{CH}_2)_r\text{NR}^m(\text{CH}_2)_s-$, -R^m is methyl, and both r and s are 3.

9. (Previously Presented): The compound according to claim 7, wherein -L- is the covalent linking biradical $-(\text{CH}_2)_r\text{NR}^m(\text{CH}_2)_s\text{NR}^m(\text{CH}_2)_t-$, both -R^m and -R^m are methyl; both r and t are 2, and s is 2 or 3.

10. (Previously Presented): The compound according to claim 1, wherein (II) is the radical (IIa").



11. (Previously Presented): The compound according to claim 10, wherein -B- is selected from the group consisting of -CONH- and -NR₁₃- .


12. (Previously Presented): The compound according to claim 10, wherein -B- is -CO[NHCHR''CO]_mO- .

13. (Previously Presented): The compound according to claim 12, wherein m = 2, the leftward -R'' is a glycine side chain, and the rightward -R'' is the arginine side chain.

14. (Previously Presented): The compound according to claim 10, wherein -R' is methyl.

15. (Previously Presented): The compound according to claim 14, wherein -L- is a single covalent bond.

16. (Previously Presented): The compound according to claim 14, wherein -L- is a biradical selected from the following ones.



17. (Previously Presented): The compound according to claim 16, wherein -L- is the biradical $-(\text{CH}_2)_r\text{NR}''(\text{CH}_2)_s-$, R''' is methyl, and both r and s are 3.

18. (Previously Presented): The compound according to claim 16, wherein -L- is the biradical $-(\text{CH}_2)_r\text{NR}''(\text{CH}_2)_s\text{NR}'''(\text{CH}_2)_t-$, both -R''' and -R'''' are methyl; both r and t are 2, and s is an integer from 2 to 3.

19. (Previously Presented): The compound according to claim 1, which is selected from the group consisting of:

N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia);

N,N'-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ib);

N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinoliny]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ic);

N-[3-[[3-[(2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Id);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ie);

N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Ig);

N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij);

N,N'-(4-methyl-4-azaheptamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Im);

N,N'-(4-methyl-4-azaheptamethylen)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iq);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iy);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iz);

(3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Iaa);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iab); and


N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iac).

20. (Previously Presented): A method for the treatment of cancer which comprises administering to a subject a therapeutically effective amount of a compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

-G₁ is a radical (II)




wherein -R' is an electron pair or a (C₁-C₃)-alkyl radical; with the condition that


(i) when -R' is an electron pair, a is a N=C double bond and the fused ring



is the biradical




thus radical (II) is (IIa'), and




(IIa')

(ii) when -R' is a (C₁-C₃)-alkyl radical, a is a N-C single bond and the fused ring

is the triradical




thus radical (II) is (IIa'');



wherein -R₁ to -R₁₂ represent radicals, same or different, selected from the group consisting of H, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein -B- is a biradical selected from the group consisting of -CONH- , -NR₁₃-, -O- , -(CH₂)_nNH- , -(CH₂)_nO- , and -CO[NHCHR''CO]_mO- ; wherein -R₁₃ is selected from the group consisting of H, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy and (C₁-C₄)-alkylamino; -R'' are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3 and m is an integer from 1 to 3;

-L- is a single covalent bond or a covalent linking biradical selected from the following ones;




wherein -R'' and -R''' are radicals, same or different, selected from the group consisting of H and (C₁-C₃)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

-G₂ is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

21. (Currently Amended): A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 1, together with appropriate amounts of pharmaceutical excipients or carriers.

22. (Previously Presented): A method of manufacturing a composition of matter comprising formula (I) and one of the following processes:


Process I:



when biradical -B- in $-G_1$ is $-CONH-$ and $-G_2$ is not an N-radical of 1,8-naphthalimide; and


wherein GP represents an amino protective group and wherein formula (IV) is a monoprotected bis-amine; or

Process II:



when biradical -B- in -G₁ is -CONH- and -G₂ is 1,8-naphthalimide; and
 wherein GP represents an amino protective group and wherein formula (IV) is a
 monoprotected bis-amine; or

Process III:



when biradical -B- is a biradical selected from a group of: $-NR_{13}-$, $-O-$, $-(CH_2)_nNH$, and $-(CH_2)_nO-$; and
 wherein GP represents an amino protective group.